Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Conditions
Interventions
Trilaciclib
Placebo
+1 more
Locations
12
United States
Ironwood Cancer & Research Centers
Phoenix, Arizona, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
Desert Hematology Oncology Medical Group, Inc
Rancho Mirage, California, United States
Innovative Clinical Research Institute - Oncology
Whittier, California, United States
Mid-Florida Hematology Oncology
Orange City, Florida, United States
Indiana University Health Goshen Cancer Center
Goshen, Indiana, United States
Start Date
April 30, 2021
Primary Completion Date
February 2, 2022
Completion Date
February 2, 2022
Last Updated
April 14, 2023
NCT05671510
NCT06043817
NCT07177937
NCT06426511
NCT07363252
NCT06257264
Lead Sponsor
G1 Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions